[1]章毅文,熊青青.重组人脑利钠肽治疗冠心病失代偿性心力衰竭的安全性及有效性[J].医学信息,2024,37(09):126-129.[doi:10.3969/j.issn.1006-1959.2024.09.024]
　ZHANG Yi-wen,XIONG Qing-qing.Safety and Efficacy of Recombinant Human Brain Natriuretic Peptide in the Treatment of Decompensated Heart Failure of Coronary Heart Disease[J].Journal of Medical Information,2024,37(09):126-129.[doi:10.3969/j.issn.1006-1959.2024.09.024]
点击复制

重组人脑利钠肽治疗冠心病失代偿性心力衰竭的安全性及有效性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年09期
页码:
126-129
栏目:
论著
出版日期:
2024-05-01

文章信息/Info

Title:
Safety and Efficacy of Recombinant Human Brain Natriuretic Peptide in the Treatment of Decompensated Heart Failure of Coronary Heart Disease
文章编号:
1006-1959（2024）09-0126-04
作者:
章毅文; 熊青青
（萍乡市第三人民医院心血管内科，江西 萍乡 337099）
Author(s):
ZHANG Yi-wen; XIONG Qing-qing
(Department of Cardiovascular Medicine,Pingxiang Third People’s Hospital,Pingxiang 337099,Jiangxi,China)
关键词:
冠心病; 代偿性心力衰竭; 心功能; 心率; 尿量
Keywords:
Coronary heart disease; Compensatory heart failure; Cardiac function; Heart rate; Urine volume
分类号:
R541
DOI:
10.3969/j.issn.1006-1959.2024.09.024
文献标志码:
A
摘要:
目的 研究重组人脑利钠肽（rh-BNP）治疗冠心病失代偿性心力衰竭（DHF）的安全性及有效性。方法 选取2020年12月-2022年12月萍乡市第三人民医院收治的60例冠心病DHF患者，按照随机数字表法分为对照组（30例）与观察组（30例），对照组行常规治疗，观察组在其基础上应用rh-BNP治疗，比较两组临床疗效、体征指标[心率（HR）、平均动脉压（MAP）、24 h尿量]、心功能[左室射血分数（LVEF）、左心室舒张末期内径（LVEDD）、心输出量（CO）]、病情程度[西雅图心绞痛量表（SAQ）、心力衰竭症状状态问卷（SSQ-HF）]及不良反应。结果 观察组治疗有效率（90.00%）高于对照组（73.33%）（P＜0.05）。两组治疗后HR、MAP低于治疗前，24 h尿量多于治疗前，且观察组HR、MAP低于对照组，24 h尿量多于对照组（P＜0.05）。两组治疗后LVEF、CO大于治疗前，LVEDD小于治疗前，且观察组LVEF、CO大于对照组，LVEDD小于对照组（P＜0.05）。两组治疗后SAQ评分高于治疗前，SSQ-HF评分低于治疗前，且观察组SAQ评分高于对照组，SSQ-HF评分低于对照组（P＜0.05）。观察组不良反应发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 rh-BNP在冠心病DHF治疗中具有较高的有效性与安全性，可调节患者体征，改善其心功能，促使病情转归，且不增加不良反应。
Abstract:
Objective To study the safety and efficacy of recombinant human brain natriuretic peptide (rh-BNP) in the treatment of decompensated heart failure (DHF) of coronary heart disease.Methods From December 2020 to December 2022, 60 patients with DHF of coronary heart disease admitted to Pingxiang Third People’s Hospital were selected and divided into control group (30 patients) and observation group (30 patients) according to the random number table method. The control group was treated with routine treatment, and the observation group was treated with rh-BNP on the basis of routine treatment. The clinical efficacy, physical signs [heart rate (HR), mean arterial pressure (MAP), 24-h urine volume], cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), cardiac output (CO) ], severity of disease [Seattle angina questionnaire (SAQ), heart failure symptom status questionnaire (SSQ-HF)] and adverse reactions were compared between the two groups.Results The effective rate of treatment in the observation group (90.00%) was higher than that in the control group (73.33%) (P<0.05). After treatment, HR and MAP in the two groups were lower than those before treatment, and 24 h urine volume was more than that before treatment, HR and MAP in the observation group were lower than those in the control group, and 24 h urine volume was more than that in the control group (P<0.05). After treatment, LVEF and CO in the two groups were higher than those before treatment, LVEDD was lower than that before treatment, and LVEF and CO in the observation group were higher than those in the control group, LVEDD was lower than that in the control group (P<0.05). After treatment, the SAQ score of the two groups was higher than that before treatment, and the SSQ-HF score was lower than that before treatment, while the SAQ score of the observation group was higher than that of the control group, and the SSQ-HF score was lower than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion rh-BNP has high efficacy and safety in the treatment of DHF in coronary heart disease.Meanwhile, it can regulate the signs of patients, improve their cardiac function, promote the prognosis of the disease, and do not increase adverse reactions.

参考文献/References:

[1]周燕,莫婷,包亚萍,等.冠心病与心力衰竭三种不同分型患者的临床特征及预后关系[J].中华医学杂志,2020,100(15):1142-1147.[2]郭瑛,孙育民,张雁,等.冻干重组人脑利钠肽联合脑啡肽酶抑制剂治疗急性失代偿性心力衰竭的临床疗效及预后分析[J].中国分子心脏病学杂志,2022,22(5):4944-4948.[3]苗艳芳,朱兵.冻干重组人脑利钠肽治疗急性失代偿性心力衰竭的临床疗效观察[J].贵州医药,2022,46(7):1040-1041.[4]庞轩,储红梅.重组人脑利钠肽联合左西孟旦治疗老年失代偿性心力衰竭的疗效及安全性[J].国际老年医学杂志,2022,43(3):330-333.[5]梁卫章,赵利平,石建平,等.冻干重组人脑利钠肽治疗冠心病心力衰竭疗效及对血流动力学、尿量、心肾功能的影响[J].现代中西医结合杂志,2021,30(20):2236-2238,2242.[6]贾妍,张瑞宁,黄柳,等.重组人脑利钠肽治疗急性失代偿性心力衰竭的临床疗效及其对血清sST2、CT-1水平的影响[J].药物评价研究,2021,44(3):545-549.[7]安乐,隋春兴,王力,等.重组人脑利钠肽不同给药方式治疗急性失代偿心力衰竭的临床效果比较[J].中华老年多器官疾病杂志,2020,19(10):769-772.[8]中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694.[9]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.[10]Guimares W,Nicz P,Garcia-Garcia HM,et al.Seattle Angina Pectoris Questionnaire and Canadian Cardiovascular Society Angina Categories in the Assessment of Total Coronary Atherosclerotic Burden[J].The American Journal of Cardiology,2021,152(1):43-48.[11]Nozaki K,Kamiya K,Hamazaki N,et al.Validity and utility of the questionnaire-based FRAIL scale in elderly patients with heart failure: findings from the FRAGILE-HF[J].European Heart Journal,2021,42(1):724.[12]符孝磊,张慧.重组人脑利钠肽可有效治疗慢性心力衰竭急性失代偿性重症[J].基因组学与应用生物学,2019,38(8):3786-3790.[13]李娜丽,陈亚军,王怀祯,等.重组人脑利钠肽治疗老年急性失代偿心力衰竭的临床研究[J].中国临床药理学杂志,2019,35(8):734-736.[14]张烜舜,孙梦雯,严光,等.冻干重组人脑利钠肽治疗老老年慢性心力衰竭患者的疗效观察[J].中华全科医学,2018,16(12):1964-1966,1999.[15]Li KP,Zhang HY,Xu XD,et al.Recombinant Human Brain Natriuretic Peptide Attenuates Myocardial Ischemia-Reperfusion Injury by Inhibiting CD4+ T Cell Proliferation via PI3K/AKT/mTOR Pathway Activation[J].Cardiovascular Therapeutics,2020,32(1):1-9.[16]王伟红,李萍,陈雨,等.左西孟旦联合冻干重组人脑利钠肽对老年难治性缺血性心肌病心衰患者的疗效研究[J].河北医药,2018,40(16):2473-2476.[17]Zile MR,Desai AS,Agarwal R,et al.Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real‐world population[J].Clinical Cardiology,2020,43(21):4-7.[18]伍鑫,王文艳,徐芸,等.左西孟旦联合重组人脑利钠肽对急性失代偿性射血分数减低的心力衰竭患者的影响[J].中华老年心脑血管病杂志,2023,25(5):465-468.[19]张文君.rhBNP联合左西孟旦治疗ADHF的临床疗效及安全性分析[J].河北医药,2018,40(11):1697-1700.[20]冯婧,鲁佳佳,赵琳.重组人脑利钠肽联合左西孟旦对老年急性失代偿性心力衰竭患者心功能和血清N末端B型脑钠肽前体及和肽素水平的影响[J].中国医药,2020,15(5):665-668.[21]魏显敬,谢莲娜,王凯君.重组人脑利钠肽对急性失代偿性心力衰竭患者血流动力学及心功能的影响[J].海南医学,2018,29(4):452-455.[22]李安娜,胡建库,王颖.左西孟旦联合rhBNP对急性失代偿性心力衰竭患者心功能的影响[J].海南医学,2020,31(19):2466-2469.[23]李静,张亮,郝六一,等.重组人脑利钠肽治疗冠心病失代偿性心力衰竭的安全性及疗效分析[J].中国药物与临床,2018,18(12):2194-2195.[24]刘文婷,胡立群,李红旗,等.重组人脑利钠肽和硝酸甘油治疗难治性心力衰竭的疗效及安全性[J].西部医学,2020,32(3):383-386.[25]黄山见,余宏斌,朱洪斌,等.重组人脑利钠肽治疗急性失代偿性心力衰竭的疗效观察[J].中西医结合心脑血管病杂志,2020,18(5):811-814.

相似文献/References:

[1]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,31(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
　YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Journal of Medical Information,2018,31(09):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[2]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,31(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
　ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Journal of Medical Information,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[3]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,31(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
　ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Journal of Medical Information,2018,31(09):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[4]张 旭.冠心病心绞痛患者进行护理干预的临床效果及 对护理质量影响研究[J].医学信息,2018,31(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
　ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Journal of Medical Information,2018,31(09):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[5]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
　XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Journal of Medical Information,2018,31(09):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[6]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与 冠状动脉病变程度的关系[J].医学信息,2018,31(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
　WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Journal of Medical Information,2018,31(09):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[7]毛红岩.冠状动脉介入治疗冠心病的疗效及 对患者血清炎症因子的影响[J].医学信息,2018,31(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
　MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Journal of Medical Information,2018,31(09):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[8]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与 冠状动脉病变程度的相关性研究[J].医学信息,2018,31(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
　YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Journal of Medical Information,2018,31(09):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[9]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
　LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Journal of Medical Information,2018,31(09):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[10]田跃雷.冠心病介入治疗后再狭窄的中西医防治[J].医学信息,2022,35(09):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
　TIAN Yue-lei.Prevention and Treatment of Restenosis After Percutaneous Coronary Intervention with Chinese and Western Medicine[J].Journal of Medical Information,2022,35(09):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]

更新日期/Last Update: 1900-01-01